Self‐reported potency · post‐prostatectomy erectile dysfunction (short‐term)
It is very uncertain whether scheduled PDE5I changes self‐reported potency compared with scheduled intraurethral prostaglandin E1 (very low certainty).
1 finding from 1 review
Erectile function · post‐prostatectomy erectile dysfunction (short‐term)
It is very uncertain whether scheduled PDE5I changes erectile function compared with scheduled intraurethral prostaglandin E1 (very low certainty).
2 findings from 1 review
Serious adverse events ‐ not reported · post‐prostatectomy erectile dysfunction (short‐term)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Sexual quality of life ‐ not reported · post‐prostatectomy erectile dysfunction (short‐term)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment discontinuation · post‐prostatectomy erectile dysfunction (short‐term)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
International Index of Erectile Function ‐ not reported · post‐prostatectomy erectile dysfunction (short‐term)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Heparin changes incidence of hepatic veno‐occlusive disease ( compared with prostaglandin E1 (very low certainty).
1 finding from 1 review
Overall survival · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality attributable to hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Heparin changes mortality attributable to hepatic veno‐occlusive disease ( compared with prostaglandin E1 (very low certainty).
1 finding from 1 review
Quality of life · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of adverse events ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Heparin changes frequency of adverse events ( compared with prostaglandin E1 (very low certainty).
1 finding from 1 review
Incidence of hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Low molecular weight heparin changes incidence of hepatic veno‐occlusive disease ( compared with prostaglandin E1 (very low certainty).
1 finding from 1 review
Overall survival · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality attributable to hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Low molecular weight heparin changes mortality attributable to hepatic veno‐occlusive disease ( compared with prostaglandin E1 (very low certainty).
1 finding from 1 review
Quality of life · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of adverse events ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Low molecular weight heparin changes frequency of adverse events ( compared with prostaglandin E1 (very low certainty).
1 finding from 1 review
Vaginal delivery not achieved within 24 hours · patients with induction of labour at term
It is very uncertain whether PGE2 changes vaginal delivery not achieved within 24 hours compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Instrumental vaginal birth · patients with induction of labour at term
(4.1) PGE2 gel showed no clear difference in instrumental vaginal delivery compared with PGE2 tablet (all women) (moderate certainty).
1 finding from 1 review